Q4 Earnings Announcements…
That’s right… Q4 earnings announcements are coming… And these five microcap stocks appear to be in an excellent position to see a surge in share price.
>>> Click here to see all 5 stocks
pixel
Samrat S. Khichi net worth and biography

Samrat Khichi Biography and Net Worth

Sam Khichi serves as executive vice president, corporate development, public policy, regulatory affairs and general counsel. He is also a member of the BD Executive Leadership Team.

Prior to his current role, Khichi served as senior vice president and general counsel of C. R. Bard, Inc., a leading medical technology company in the fields of vascular, urology and surgical specialty products, which BD acquired in 2017.

Khichi’s prior experience includes serving as senior vice president, chief administrative officer and general counsel for Catalent Pharmaceutical Solutions; counsel at O’Melveny & Myers LLP, specializing in mergers, acquisitions and private equity; and mergers and acquisitions attorney at Shearman & Sterling.

He also previously served as a reserve officer in the United States Navy, an active duty field artillery officer in the United States Army and a White House Fellow appointed by President George W. Bush.

Khichi earned a bachelor’s degree in business from Georgetown University, a juris doctorate in law from Fordham University School of Law and a master’s degree in business administration from the Northwestern University Kellogg School of Management.

What is Samrat S. Khichi's net worth?

The estimated net worth of Samrat S. Khichi is at least $1.50 million as of August 9th, 2022. Mr. Khichi owns 5,928 shares of Becton, Dickinson and stock worth more than $1,496,109 as of December 3rd. This net worth approximation does not reflect any other assets that Mr. Khichi may own. Additionally, Mr. Khichi receives an annual salary of $1,460,000.00 as EVP at Becton, Dickinson and. Learn More about Samrat S. Khichi's net worth.

How old is Samrat S. Khichi?

Mr. Khichi is currently 55 years old. There are 4 older executives and no younger executives at Becton, Dickinson and. Learn More on Samrat S. Khichi's age.

What is Samrat S. Khichi's salary?

As the EVP of Becton, Dickinson and Company, Mr. Khichi earned a total compensation package of $3,531,158.00 in 2021. Mr. Khichi earned a salary of $700,833.00, stock awards of $1,011,960.00, non-equity compensation of $724,141.00, and other compensation of $39,676.00.The highest earning executive at Becton, Dickinson and is Mr. Thomas E. Polen Jr., Pres, CEO & Chairman, who commands a salary of $3,690,000.00 per year. Learn More on Samrat S. Khichi's salary.

How do I contact Samrat S. Khichi?

The corporate mailing address for Mr. Khichi and other Becton, Dickinson and executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and can also be reached via phone at (201) 847-6800. Learn More on Samrat S. Khichi's contact information.

Has Samrat S. Khichi been buying or selling shares of Becton, Dickinson and?

Samrat S. Khichi has not been actively trading shares of Becton, Dickinson and during the last quarter. Most recently, Samrat S. Khichi sold 9,185 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $260.44, for a transaction totalling $2,392,141.40. Following the completion of the sale, the executive vice president now directly owns 5,928 shares of the company's stock, valued at $1,543,888.32. Learn More on Samrat S. Khichi's trading history.

Who are Becton, Dickinson and's active insiders?

Becton, Dickinson and's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and?

During the last year, insiders at the medical instruments supplier sold shares 10 times. They sold a total of 45,277 shares worth more than $12,052,252.30. The most recent insider tranaction occured on August, 15th when EVP David Hickey sold 475 shares worth more than $125,875.00. Insiders at Becton, Dickinson and own 0.5 % of the company. Learn More about insider trades at Becton, Dickinson and.

Information on this page was last updated on 8/15/2022.

Samrat S. Khichi Insider Trading History at Becton, Dickinson and

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2022Sell9,185$260.44$2,392,141.405,928View SEC Filing Icon  
5/21/2019Sell16,085$234.68$3,774,827.8012,608View SEC Filing Icon  
See Full Table

Samrat S. Khichi Buying and Selling Activity at Becton, Dickinson and

This chart shows Samrat S Khichi's buying and selling at Becton, Dickinson and by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Overview

Becton, Dickinson and logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $252.38
Low: $247.76
High: $252.59

50 Day Range

MA: $229.12
Low: $218.29
High: $250.83

2 Week Range

Now: $252.38
Low: $215.90
High: $280.62

Volume

1,326,153 shs

Average Volume

1,239,989 shs

Market Capitalization

$71.52 billion

P/E Ratio

42.92

Dividend Yield

1.39%

Beta

0.61
Q4 Earnings Announcements…
That’s right… Q4 earnings announcements are coming… And these five microcap stocks appear to be in an excellent position to see a surge in share price.
>>> Click here to see all 5 stocks
pixel